Overview A Long-Term Study to Evaluate the Safety of Asoprisnil and Estrogen Administration to Postmenopausal Women Status: Completed Trial end date: 2001-12-01 Target enrollment: Participant gender: Summary The objective of this study is to determine the long-term safety of asoprisnil 10 mg when administered to postmenopausal women with Premarin® 0.625 mg Phase: Phase 2 Details Lead Sponsor: AbbottTreatments: EstrogensEstrogens, Conjugated (USP)